219 related articles for article (PubMed ID: 11719225)
21. The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome.
Gao F; Maiti S; Sun G; Ordonez NG; Udtha M; Deng JM; Behringer RR; Huff V
Mol Cell Biol; 2004 Nov; 24(22):9899-910. PubMed ID: 15509792
[TBL] [Abstract][Full Text] [Related]
22. Repression of CMIP transcription by WT1 is relevant to podocyte health.
Moktefi A; Zhang SY; Vachin P; Ory V; Henique C; Audard V; Rucker-Martin C; Gouadon E; Eccles M; Schedl A; Heidet L; Ollero M; Sahali D; Pawlak A
Kidney Int; 2016 Dec; 90(6):1298-1311. PubMed ID: 27650733
[TBL] [Abstract][Full Text] [Related]
23. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation.
Davies JA; Ladomery M; Hohenstein P; Michael L; Shafe A; Spraggon L; Hastie N
Hum Mol Genet; 2004 Jan; 13(2):235-46. PubMed ID: 14645201
[TBL] [Abstract][Full Text] [Related]
24. The Wilms' tumor suppressor Wt1 encodes a transcriptional activator of the class IV POU-domain factor Pou4f2 (Brn-3b).
Wagner KD; Wagner N; Schley G; Theres H; Scholz H
Gene; 2003 Feb; 305(2):217-23. PubMed ID: 12609742
[TBL] [Abstract][Full Text] [Related]
25. The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.
Wells J; Rivera MN; Kim WJ; Starbuck K; Haber DA
Mol Cancer Res; 2010 Jul; 8(7):975-85. PubMed ID: 20571064
[TBL] [Abstract][Full Text] [Related]
26. Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome.
Vicanek C; Ferretti E; Goodyer C; Torban E; Moffett P; Pelletier J; Goodyer P
Kidney Int; 1997 Sep; 52(3):614-9. PubMed ID: 9291179
[TBL] [Abstract][Full Text] [Related]
27. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
28. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1.
Wagner N; Wagner KD; Xing Y; Scholz H; Schedl A
J Am Soc Nephrol; 2004 Dec; 15(12):3044-51. PubMed ID: 15579507
[TBL] [Abstract][Full Text] [Related]
29. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
[TBL] [Abstract][Full Text] [Related]
30. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity.
Rivera MN; Kim WJ; Wells J; Stone A; Burger A; Coffman EJ; Zhang J; Haber DA
Proc Natl Acad Sci U S A; 2009 May; 106(20):8338-43. PubMed ID: 19416806
[TBL] [Abstract][Full Text] [Related]
31. Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations.
Menendez-Castro C; Hilgers KF; Amann K; Daniel C; Cordasic N; Wachtveitl R; Fahlbusch F; Plank C; Dötsch J; Rascher W; Hartner A
Nephrol Dial Transplant; 2013 Jun; 28(6):1407-17. PubMed ID: 23229934
[TBL] [Abstract][Full Text] [Related]
32. Induction of p21 by the Wilms' tumor suppressor gene WT1.
Englert C; Maheswaran S; Garvin AJ; Kreidberg J; Haber DA
Cancer Res; 1997 Apr; 57(8):1429-34. PubMed ID: 9108440
[TBL] [Abstract][Full Text] [Related]
33. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
34. Identification of connective tissue growth factor as a target of WT1 transcriptional regulation.
Stanhope-Baker P; Williams BR
J Biol Chem; 2000 Dec; 275(49):38139-50. PubMed ID: 10973960
[TBL] [Abstract][Full Text] [Related]
35. A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis.
Benetti E; Caridi G; Malaventura C; Dagnino M; Leonardi E; Artifoni L; Ghiggeri GM; Tosatto SC; Murer L
Clin J Am Soc Nephrol; 2010 Apr; 5(4):698-702. PubMed ID: 20150449
[TBL] [Abstract][Full Text] [Related]
36. A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome.
Patek CE; Little MH; Fleming S; Miles C; Charlieu JP; Clarke AR; Miyagawa K; Christie S; Doig J; Harrison DJ; Porteous DJ; Brookes AJ; Hooper ML; Hastie ND
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2931-6. PubMed ID: 10077614
[TBL] [Abstract][Full Text] [Related]
37. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
[TBL] [Abstract][Full Text] [Related]
38. The human sex-determining gene SRY is a direct target of WT1.
Hossain A; Saunders GF
J Biol Chem; 2001 May; 276(20):16817-23. PubMed ID: 11278460
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1.
Matsuzawa-Watanabe Y; Inoue J; Semba K
Oncogene; 2003 Sep; 22(39):7900-4. PubMed ID: 12970737
[TBL] [Abstract][Full Text] [Related]
40. A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1.
Viney RL; Morrison AA; van den Heuvel LP; Ni L; Mathieson PW; Saleem MA; Ladomery MR
Proteomics; 2007 Mar; 7(5):804-15. PubMed ID: 17295355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
